Emerging Anticancer Therapeutic Targets and the Cardiovascular System: is There Cause for Concern?

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2010 Apr 3

PMID 20360265

Citations 15

Authors

Xuyang Peng

Laura Pentassuglia

Douglas B Sawyer

Affiliations

Soon will be listed here.

Abstract

The race for a cure to cancer continues, fueled by unprecedented discoveries of fundamental biology underlying carcinogenesis and tumorigenesis. The expansion of the target list and tools to approach them is moving the oncology community extraordinarily rapidly to clinical trials, bringing new hope for cancer patients. This effort is also propelling biological discoveries in cardiovascular research, because many of the targets being explored in cancer play fundamental roles in the heart and vasculature. The combined efforts of cardiovascular and cancer biologists, along with clinical investigators in these fields, will be needed to understand how to safely exploit these efforts. Here, we discuss a few of the many research foci in oncology where we believe such collaboration will be particularly important.

Citing Articles

Targeting transcription factors in cancer drug discovery.

Mitra P Explor Target Antitumor Ther. 2022; 1(6):401-412.

PMID: 36046384 PMC: 9402400. DOI: 10.37349/etat.2020.00025.

Induction of the ER stress response in NRVMs is linked to cardiotoxicity caused by celastrol.

Chen Z, Zhuang Z, Meng C, Zhu Z, Zhang Y, Zhang Z Acta Biochim Biophys Sin (Shanghai). 2022; 54(8):1180-1192.

PMID: 35983978 PMC: 9827806. DOI: 10.3724/abbs.2022104.

Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties.

Okada M, Nakagawa-Saito Y, Mitobe Y, Sugai A, Togashi K, Suzuki S Int J Mol Sci. 2022; 23(15).

PMID: 35955917 PMC: 9369372. DOI: 10.3390/ijms23158785.

Natural and Synthetic Lactones Possessing Antitumor Activities.

Kim Y, SenGupta S, Sim T Int J Mol Sci. 2021; 22(3).

PMID: 33494352 PMC: 7865919. DOI: 10.3390/ijms22031052.

Cyanine conjugates in cancer theranostics.

Li Y, Zhou Y, Yue X, Dai Z Bioact Mater. 2020; 6(3):794-809.

PMID: 33024900 PMC: 7528000. DOI: 10.1016/j.bioactmat.2020.09.009.

References

Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T . Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest. 2000; 106(12):1511-9. PMC: 387252. DOI: 10.1172/JCI10226. View

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

Tischoff I, Wittekind C, Tannapfel A . Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2006; 13(4):274-9. DOI: 10.1007/s00534-005-1055-3. View

Athar M, Tang X, Lee J, Kopelovich L, Kim A . Hedgehog signalling in skin development and cancer. Exp Dermatol. 2006; 15(9):667-77. DOI: 10.1111/j.1600-0625.2006.00473.x. View

Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E . Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 2004; 6(5):673-84. DOI: 10.1016/s1534-5807(04)00107-8. View

Szyf M . The DNA methylation machinery as a target for anticancer therapy. Pharmacol Ther. 1996; 70(1):1-37. DOI: 10.1016/0163-7258(96)00002-2. View

Abdel-Ghany M, Cheng H, Elble R, Pauli B . Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth. J Biol Chem. 2002; 277(37):34391-400. DOI: 10.1074/jbc.M205307200. View

Kantarjian H, Cortes J, Kim D, Dorlhiac-Llacer P, Pasquini R, DiPersio J . Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009; 113(25):6322-9. PMC: 4916944. DOI: 10.1182/blood-2008-11-186817. View

Kaneda R, Takada S, Yamashita Y, Choi Y, Nonaka-Sarukawa M, Soda M . Genome-wide histone methylation profile for heart failure. Genes Cells. 2008; 14(1):69-77. DOI: 10.1111/j.1365-2443.2008.01252.x. View

10.

Rappolee D, Iyer A, Patel Y . Hepatocyte growth factor and its receptor are expressed in cardiac myocytes during early cardiogenesis. Circ Res. 1996; 78(6):1028-36. DOI: 10.1161/01.res.78.6.1028. View

11.

Falsone S, Gesslbauer B, Tirk F, Piccinini A, Kungl A . A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett. 2005; 579(28):6350-4. DOI: 10.1016/j.febslet.2005.10.020. View

12.

Beg A, Baltimore D . An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996; 274(5288):782-4. DOI: 10.1126/science.274.5288.782. View

13.

Yang H, Zonder J, Dou Q . Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs. 2009; 18(7):957-71. PMC: 3758888. DOI: 10.1517/13543780903002074. View

14.

Chang S, McKinsey T, Zhang C, Richardson J, Hill J, Olson E . Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004; 24(19):8467-76. PMC: 516756. DOI: 10.1128/MCB.24.19.8467-8476.2004. View

15.

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S . The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009; 23(6):1019-28. DOI: 10.1038/leu.2008.397. View

16.

Eble D, Strait J, Govindarajan G, Lou J, Byron K, Samarel A . Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase. Am J Physiol Heart Circ Physiol. 2000; 278(5):H1695-707. DOI: 10.1152/ajpheart.2000.278.5.H1695. View

17.

Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E . Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 1996; 56(8):1775-85. View

18.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

19.

Medina V, Calvo M, Diaz-Prado S, Espada J . Hedgehog signalling as a target in cancer stem cells. Clin Transl Oncol. 2009; 11(4):199-207. DOI: 10.1007/s12094-009-0341-y. View

20.

Cheng W, Reiss K, Kajstura J, Kowal K, Quaini F, Anversa P . Down-regulation of the IGF-1 system parallels the attenuation in the proliferative capacity of rat ventricular myocytes during postnatal development. Lab Invest. 1995; 72(6):646-55. View